Rowan (Analyst)'s questions to Catalyst Pharmaceuticals Inc (CPRX) leadership • Q4 2024
Question
An analyst named Rowan, on for Leland Gershell, asked how the greater clarity on FIRDAPSE's IP protection shapes future investment in the franchise and the company's broader business development approach. They also questioned the drivers behind the lower FYCOMPA guidance, given the typical brand adherence in epilepsy.
Answer
CEO Richard Daly explained that with a potential 10-year runway for FIRDAPSE, the company will explore all avenues to optimize its value, including more aggressive investment in the oncology/SCLC segment and other life cycle management opportunities. Regarding FYCOMPA, Daly clarified that while brand adherence is strong, the guidance reflects the inevitable erosion from both price concessions to payers and volume loss to generics once the patent expires, though he reiterated the decline would be more gradual than for a typical retail drug.